Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015340 · ClinicalTrials.gov registry record · Phase 4
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
A Phase 4 study of Substance-Related Disorders and Opioid Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 4
- Development phase
- 582
- Enrollment target
- 5
- Study locations
NCT00015340 is a Phase 4 study of Substance-Related Disorders and Opioid Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 582 participants, below the 1,511-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (61% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00015340, a Phase 4 study of Substance-Related Disorders and Opioid Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 582 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is the safety and efficacy of Buprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.
Conditions Studied
Interventions
- DRUG Buprenorphine/naloxone
Study Locations (5)
California
- University of California - Los Angeles
Florida
- VA Medical Center - Tampa
Illinois
- VA Medical Center - Hines
New York
- New York VAMC - New York
Washington
- VA PUget Sound Helath Care System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 1999-08 |
| Est. Completion | 2001-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00015340
The ClinicalTrials.gov registry entry for NCT00015340 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 582 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (61% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.
NCT00015340 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00015340 about?
NCT00015340 is a clinical study titled "Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14". The purpose of this study is the safety and efficacy of Buprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.
What is the current status of trial NCT00015340?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 582 participants. The study started on 1999-08. Estimated completion is 2001-09.
What conditions does trial NCT00015340 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Opioid Dependence.
What interventions are being tested in trial NCT00015340?
The interventions under investigation include: Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT00015340?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00015340 being conducted?
This trial has 5 study locations across California, Florida, Illinois, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modeling Impaired Judgement in Cocaine Abusers - 6
COMPLETED · Phase 4
-
Quetiapine for Cocaine Use and Cravings
COMPLETED · Phase 4
-
Relapse Prevention With Varenicline
COMPLETED · Phase 4
-
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.